Navigation Links
Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/31/2009

II SEPIA-ACS1/ TIMI-42 study randomized 3241 patients from 36 countries in 6 treatment arms. The study assessed the efficacy and safety of five different doses of otamixaban versus the standard unfractionated heparin plus Glycoprotein IIb/IIIa inhibitor (eptifibatide), on background of standard dual antiplatelet therapy, in patients with high-risk non-ST-elevation acute coronary syndromes. SEPIA-ACS1 study showed that otamixaban displayed clinically meaningful activity on the primary endpoint from the threshold dose of 0.070 mg/kg/h, the second tested dose, with a consistent antithrombotic effect up to the 5th highest tested dosage. The lowest studied dosage was prematurely stopped due to insufficient activity, based on recommendation by an independent data monitoring board. Moreover a combined analysis of the intermediate doses (0.105 and 0.140 mg/kg/h) of otamixaban arms showed that otamixaban reduced by approximately 46 percent (p=0.0198) the risk of the composite of death or a second myocardial infarction, a predefined study secondary efficacy endpoint.

The potent antithrombotic effect of otamixaban was also accompanied with a dose-dependent bleeding profile. Combined intermediate otamixaban dosages showed a safety profile not statistically different with regard to TIMI major or minor bleeding through 7 days, in comparison to UFH and GPIIb/IIIa inhibitor comparator (RR 1.20, 95% CI 0.64-2.27, p=0.5634).

'The SEPIA-ACS1 trial is providing very encouraging results for a new and more effective treatment approach', said Marc Cluzel, MD Senior Vice President Research and Development sanofi-aventis. 'We aim, on the basis of these findings to address through our development program remaining patients', practionners' and payers' needs for management of ACS.'

Acute Coronary Syndromes is a general term used to regroup clinical symptoms related to acute myocardial ischemia. ACS represents an area of importa
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
2. Sanofi-aventis Stands Behind the Safety of Lantus(R)
3. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
8. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
9. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
10. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
11. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... MELBOURNE, Australia , Sept. 18, 2014 ... appointments of Dr. Ashraf Hanna , M.D., Ph.D., ... its Board of Directors. Dr. Hanna is the Vice ... and Chief Financial Officer for the Genentech Foundation, while ... Global Head of Business Development and Licensing for Roche ...
(Date:9/18/2014)... 18, 2014 Relmada Therapeutics, Inc., (OTCQB: RLMD), ... of chronic pain, announced today that it has appointed ... of  Senior Director of Clinical Development. During ... established and led successful global clinical operations teams, in ... facilitate the clinical development of numerous therapeutics and diagnostics ...
(Date:9/18/2014)... new expert panel report, Improving Medicines for Children ... by the Council of Canadian Academies, addresses the importance ... year about half of Canada,s ... Much of this prescribing is done off-label (i.e. the ... risks. Children have historically been excluded in ...
Breaking Medicine Technology:Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 2Nexvet Appoints Ashraf Hanna and Joseph McCracken to Board of Directors 3Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 2Studying medicines in children is always possible and is in their best interest, finds Expert Panel 3
(Date:9/18/2014)... One of the most capable and ... ShandsCair Flight Program’s new EC155 B1, will ... at the Air Medical Transport Conference (AMTC), Sept. 22-24, ... into service ShandsCair EC155 and the Vanderbilt University ... AMTC highlight Airbus Helicopters broad, industry leading line-up of ...
(Date:9/18/2014)... THURSDAY, Sept. 18, 2014 (HealthDay News) -- Daily supplements ... protect against the development of age-related cataracts among men, ... suggested that one or both could help prevent cataracts. ... Women,s Hospital and Harvard Medical School in Boston, and ... of selenium and vitamin E. The trial was initially ...
(Date:9/18/2014)... UT (PRWEB) September 18, 2014 Thousands ... will be recognizing their shared fundraising impact on 127 ... Sept. 25. , The first-ever Dance Marathon Day will ... $20 million projected to be raised by college and ... CMN Hospital. Donations generated through Dance Marathon campus programs ...
(Date:9/18/2014)... A group of international scientists have developed a new ... here . , The Wildlife Conservation Society (WCS)-led ... Tropical Diseases , describes the use of fecal samples ... have been exposed to the virus. This represents a ... can potentially change the way Ebola virus is studied ...
(Date:9/18/2014)... the Ebola virus invoke scary scenarios of deadly epidemics, ... are still providing researchers with new insights on how ... published online Sept. 18, 2014, in the journal ... Medical School Singapore detail how the Yersinia pestis bacteria ... the lymph nodes and eventually ride into the lungs ...
Breaking Medicine News(10 mins):Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 2Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 3Health News:Airbus Helicopters Inc. Features Industry-leading Models at AMTC 4Health News:Vitamin E, Selenium Supplements Don't Seem to Prevent Cataracts 2Health News:250 Campuses Usher in School Year of Saving Kids’ Lives During First-Ever “Dance Marathon Day” on Sept. 25 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 2Health News:Research yields a game changer for improving understanding of Ebola and great apes 3Health News:New insights on an ancient plague could improve treatments for infections 2
... , PASO ROBLES, Calif., July 28 ... California, will make silicone micro-implants such as surgical drains, catheter ... not routine is the incredibly precise tolerances demanded of these ... achieving consistently precise results to within .001 inch is no ...
... , MAITLAND, Fla. , July 28 ... treatment for infants with plagiocephaly and other head shape abnormalities, opened ... The Center currently also has offices in the Baltimore and Dallas ... orthoses, also commonly referred to as a cranial helmets or headbands. ...
... HARBIN, China, July 28 /PRNewswire-Asia-FirstCall/ -- China ... Company") (Nasdaq: CSKI ), a,leading fully integrated ... China ("PRC"), today announced that the,Company is scheduled to ... in early August, 2009. , ...
... , VANCOUVER, July 28 /PRNewswire-FirstCall/ - QLT Inc. (NASDAQ: ... "Company") today announced encouraging interim data from an ongoing ... the punctal plug delivery system. These studies are part ... QLT,s wholly-owned subsidiary, QLT Plug Delivery, Inc. , Preliminary ...
... , , THE WOODLANDS, Texas, ... LXRX ), a biopharmaceutical company focused on discovering and developing breakthrough ... financial results for the three months and six months ended June 30, ... progress, including the recent initiation of a Phase 2 study of LX1032 ...
... MINNEAPOLIS, July 28 ATS Medical, Inc. (Nasdaq: ATSI ... that it will participate in two upcoming investor conferences. ... The Company will participate in the 9th Annual BMO ... in New York. Michael Kramer, CFO of ATS Medical, will ...
Cached Medicine News:Health News:When You Make Things That Get Implanted in People, Small Things Count 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 2Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 3Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 4Health News:New STAR Cranial Center of Excellence Offers Cutting-Edge Treatment to Central Florida Infants 5Health News:China Sky One Medical, Inc. to Conduct Non-Deal Roadshow in Hong Kong and Singapore 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 2Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 3Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 4Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 5Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 6Health News:QLT announces interim data from a Phase II clinical trial and a device study for the Punctal Plug Drug Delivery System 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 2Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 3Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 4Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 5Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 6Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 7Health News:Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Second Quarter Financial Results 8Health News:ATS Medical to Participate at Upcoming Investor Conferences 2
... Constructed of optical steel base ... overlay. Comes with custom fitted ... create a seal to the ... from oblique angle exposure. Includes ...
... protection Properly manufactured radiation protective eyewear ... Our high quality frames and materials offer ... weight. Our lenses are made of Schott ... industry standards. Most Pulse Glasses are offered ...
... designed with the safety and comfort of the ... (also called SF-6) leaded glass, the industry standard ... as set for optical clarity, visible light transmission, ... is protecting your eyes, it also helps you ...
B-52 Wrap Frame...
Medicine Products: